Journal
TRENDS IN CARDIOVASCULAR MEDICINE
Volume 27, Issue 5, Pages 352-359Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2016.08.008
Keywords
Human genetics; Cardiovascular disease
Categories
Funding
- NIH/NHLBI, United States [K08HL114642, R01HL131961]
- Foundation for Barnes-Jewish Hospital, United States
- Massachusetts General Hospital (MGH)
- Donovan Family Foundation, United States [R01HL107816]
- Merck, United States
- Fondation Leducq, France
Ask authors/readers for more resources
Identifying appropriate molecular targets is a critical step in drug development. Despite many advantages, the traditional tools of observational epidemiology and cellular or animal models of disease can be misleading in identifying causal pathways likely to lead to successful therapeutics. Here, we review some favorable aspects of human genetics studies that have the potential to accelerate drug target discovery. These include using genetic studies to identify pathways relevant to human disease, leveraging human genetics to discern causal relationships between biomarkers and disease, and studying genetic variation in humans to predict the potential efficacy and safety of inhibitory compounds aimed at molecular targets. We present some examples taken from studies of plasma lipids and coronary artery disease to highlight how human genetics can accelerate therapeutics development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available